Valuing the effect sizes hypothesized in phase 3 trials of targeted therapies in oncology
This abstract was not included in this publication as it was already published. See Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 317P (10.1093/annonc/mdw366.02) - Oxford University Press.
Autores principales: | Reilly, G, Wise, A, Attwood, S, Scudder, C, Love, S |
---|---|
Formato: | Conference item |
Publicado: |
BioMed Central
2017
|
Ejemplares similares
-
The changing world of clinical trials 2003-2017: A view from the AspECT trial
por: Reilly, G, et al.
Publicado: (2017) -
Leveraging homologous hypotheses for increased efficiency in tumor growth curve testing
por: Alan D. Hutson, et al.
Publicado: (2023-11-01) -
Conducting tests of hypotheses: the need for an adequate sample size
por: Mohd. Asraf, Ratnawati, et al.
Publicado: (2004) -
Sample size determination for Bayesian ANOVAs with informative hypotheses
por: Qianrao Fu, et al.
Publicado: (2022-11-01) -
THz therapy and smoking: facts and hypotheses
por: Svetlana S. Parshina
Publicado: (2013-11-01)